Act quickly to manage bleeding in patients taking direct oral anticoagulants

AbstractDirect oral anticoagulants (DOACs) are increasingly preferred anticoagulation options, with a lower risk of intracranial haemorrhage versus warfarin. Bleeding is, however, a predictable adverse event requiring urgent management. Specific DOAC reversal agents may be available, such as idarucizumab for the thrombin inhibitor dabigatran, and andexanet alfa for the factor Xa inhibitors apixaban, edoxaban (off-label) and rivaroxaban; but prothrombin complex concentrates are still often used in addition to supportive measures and haemostatic support.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research